Interferon-based hepatitis C treatment in patients with pre-existing severe mental illness and substance use disorders

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 3, 2009, Pages 363-376

  Freedman, Kenneth ^a   Nathanson, Jay ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Buprenorphine; Compliance; Depression; Drug addiction; Hepatitis C; IFN ; Methadone; Psychiatric; Substance abuse

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIDEPRESSANT AGENT; BUPRENORPHINE; CANNABIS; COCAINE; DIAMORPHINE; INTERFERON; METHADONE; METHAMPHETAMINE; NALTREXONE; OPIATE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RIBAVIRIN;

ABSTINENCE; ALCOHOL ABUSE; BLEEDING; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG DEPENDENCE TREATMENT; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; GENOTYPE; HEPATITIS C; HUMAN; MAJOR DEPRESSION; MENTAL DISEASE; METHADONE TREATMENT; OPIATE ADDICTION; OVERALL SURVIVAL; PATIENT COMPLIANCE; PREVALENCE; REVIEW; SCHIZOPHRENIA; SUBSTANCE ABUSE; TREATMENT INDICATION; ADDICTION; DRUG COMBINATION; DRUG EFFECT; HEPATITIS C VIRUS; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; MENTAL DISORDERS; POLYETHYLENE GLYCOLS; RIBAVIRIN; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 67649099664     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/ERI.09.1     Document Type: Review

References (42)

1. Rosenberg SD, Swanson JW, Wolford GL et al. Blood-borne infections and persons with mental illness: the five-site health and tisk study of blood-borne infections among persons with severe mental illness. Psychiatr. Serv. 54(6), 827-835 (2003).
2. Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 341, 556-562 (1999).
3. Litwin AH, Soloway I, Gourevitch MN. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. Clin. Infect. Dis. 40, S339-S345 (2005).
4. Sherman KE, New paradigms in the management of hepatitis C virus co-infections Nat. Clin. Pract. Gastroenterol. Hepatol. 4(Suppl. 1), S10-S16 (2007).
5. Management of hepatitis C. NIH Consens. Statement 15(3), 1-41 (1997).
6. Loftis JM, Hauser P. Hepatitis C in patients with psychiatric disease and substance abuse: screening strategies and comanagement models of care. Curr. Hepat. Rep. 2, 93-100 (2003).
7. Schaefer M, Heinz A, Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction 99, 1167-1175 (2004).
8. Sullivan LE, Fiellin DA. Hepatitis C and HIV infections: implications for clinical care in injection drug users. Am. J. Addict. 13, 1-20 (2004).
9. Sylvestre DL, Loftis JM, Hauser P et al. Co-occurring hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care. J. Urban Health 81(4), 719-734 (2004).
10. Jeffrey GP, MacQuillan G, Chua F et al. Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants. Hepatology 45(1), 111-117 (2007).
11. Witthoeft T, Fuchs M, Ludwig D. Recent i.v.-drug users with chronic hepatitis C can be efficiently treated with daily high dose induction therapy using consensus interferon: an open-label pilot study. World J. Gastroenterol. 13(4), 579-584 (2007).
12. Guadagnino V, Trotta MP, Montesano F et al. Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxification programmes. Addiction 102(3), 423-431 (2007).
13. Grebely J, Raffa JD, Meagher C et al. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. J. Gastroenterol. Hepatol. 22(9), 1519-1525 (2007).
14. Huber M, Weber R, Oppliger R et al. Interferon α-2a plus ribavirin 1,000/1,200 mg versus interferon α-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial. Infection 33(1), 25-29 (2005).
15. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 40(1), 120-124 (2004).
16. Van Thiel DH, Anantharaju A, Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am. J. Gastroenterol. 98(10), 2281-2288 (2003).
17. Robaeys G, Van Vlierberghe H, Mathei C et al. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur. J. Gastroenterol. Hepatol. 18(2), 159-166 (2006).
18. Schaefer M, Schmidt F, Folwaczny C et al. Adherence and mental side effects during hepatitis C treatment with interferon α and ribavirin in psychiatric risk groups. Hepatology 37, 443-451 (2003).
19. Sulkowski M, Wright T, Rossi S et al. Peginterferon α-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. Clin. Pharmacol. Ther. 77(3), 214-224 (2005).
20. Gupta SK, Sellers E, Somoza E, Angles L, Kolz K, Cutler DL. The effect of multiple doses of peginterferon α-2b on the steady-state pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. J. Clin. Pharmacol. 47(5), 604-612 (2007).
21. Berk SI, Litwin AH, Arnsten JH, Du E, Soloway I, Gourevitch MN. Effects of pegylated interferon α-2b on the pharmacokinetic and pharmacodynamic properties of methadone: a prospective, nonrandomized, crossover study in patients coinfected with hepatitis C and HIV receiving methadone maintenance treatment. Clin. Ther. 29(1), 131-138 (2007).
22. Freedman K, McLaughlin P, Strong P. Treatment of hepatitis C infected substance abusers-within a community-based, outpatient methadone maintenance program. Am. J. Gastroenterol. 100(9), S111 (2005).
23. Matthews G, Kronberg IJ, Dore GJ. Treatment for hepatitis C virus infection among current injection drug users in Australia. Clin. Infect. Dis. 40(Suppl, 5), S325-S329 (2005).
24. Rifai MA, Moles JK, Lehman LP, Van der Linden BJ. Hepatitis C screening and treatment outcomes in patients with substance use/dependence disorders. Psychosomatics 47 {2), 112-121 (2006).
25. Krook AL, Stokka D, Heger B, Nygaard E. Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study. Eur. Addict. Res. 13(4), 216-221 (2007).
26. Freudenreich O, Gandhi RT, Walsh JP et al. Hepatitis C in schizophrenia: screening experience in a community-dwelling clozapine cohort. Psychosomatics 48, 405-411 (2007).
27. Strader DB, Wright T, Thomas DL, Seef LB. Diagnosis management and treatment of hepatitis C (AASLD Practice Guidelines). Hepatology 39(4), 1147-1171 (2004).
28. Rifai MH, Indest D, Loftis J, Hauser P. Psychiatric management of the hepatitis C patient. Curr. Treat. Options Gastroenterol. 9, 508-619 (2006).
29. Schaefer M, Schwaiger M, Garkisch AS et al. Prevention of interferon-α associated depression in psychiatric risk patients with chronic hepatitis C. J. Hepatol. 42, 793-798 (2005).
30. Schaefer M, Schmidt F, Folwaczny C et al. Adherence and mental side effects during hepatitis C treatment with interferon α and ribavirin in psychiatric risk groups. Hepatology 37, 433-451 (2003).
31. Mistler LA, Brunette MF, Marsh BJ, Vidaver RM, Luckoor R, Rosenberg SD. Hepatitis C treatment for people with severe mental illness. Psychosomatics 47, 93-107 (2006).
32. McGovern B, Fiore J, Wurcel A et al. Delivering therapy for hepatitis C virus infection to incarcerated HIV-seropositive patients. Clin. Infect. Dis. 41(Suppl. 1), S56-S62 (2005).
33. Rifai MA, Moles JK, Short DD. Hepatitis C treatment eligibility and outcomes among patients with psychiatric illness. Psychiatr. Serv. 57(4), 570-572 (2006).
34. Schaefer M, Hinzpeter A, Mohmand A et al. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-α and ribavirin: response and psychiatric side effects. Hepatology 46(4), 991-998 (2007).
35. Taylor LE. Delivering care to injection drug users coinfected with HIV and hepatitis C virus. Clin. Infect. Dis. 40(Suppl. 5), S355-S361 (2005).
36. Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN. The impact of barriers to HCV treatment in recovering heroin users maintained on methadone. J. Subst. Abuse Treat. 29, 159-165 (2005).
37. Sylvestre DL. Approaching treatment for hepatitis C virus infection in substance users. Clin. Infect. Dis. 41(Suppl. 1), S79-S82 (2005).
38. Sylvestre DL, Clements BJ, Malibu Y. Cannabis use improves retention and virological outcomes in patients treated for hepatitis C. Eur. J. Gastroenterol. Hepatol. 18(10), 1057-1063 (2006).
39. Guadagnino V, Trotta MP, Carioti J, Caroleo B, Antinori A (for the Nocchiero Study Group). Does depression symptomatology affect medication compliance during the first weeks of anti-HCV therapy in intravenous drug users? Dig. Liver Dis. 38(2), 119-124 (2006).
40. Hallinan R, Byrne A, Agho K, Dore GJ, Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug Alcohol Depend. 88(1), 49-53 (2007).
41. Grebely J, Genoway K, Khara M et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int. J. Drug Policy 18(5), 437-443 (2007).
42. Berk SI, Litwin AH, Du Y, Cruikshank G, Gourevitch MN, Arnsten JH. False reduction in serum methadone concentrations by BD Vacutainer® Serum Separator Tubes (SST™). Clin. Chem. 52(10), 1972-1974 (2006).